Treatment with nivolumab and ipilimumab results in modest response rates for patients with ACC, but not non‐ACC SGC, with results comparable to previously conducted studies on dual checkpoint inhibition [17, 37] and PD‐1/PD‐L1 monotherapy [16, 25, 30, 31, 32, 33]. This evidence concerns the gene CD274 and adrenal cortex carcinoma.